Risk factors for immune-related adverse effects during CPI therapy in patients with head and neck malignancies - a single center study.

ABSTRACT:

Introduction

Checkpoint inhibitors, such as PD1 inhibitors, represent an important pillar in the therapy of advanced malignancies of the head and neck region. The most relevant complications are immune-related adverse effects (irAEs), which represent an immense burden for patients. Currently, no sufficient stratification measures are available to identify patients at increased risk of irAEs. The aim of this retrospective study was to examine whether demographic, histopathological, clinical, or laboratory values at the start of CPI therapy represent a risk factor for the later occurrence of autoimmune complications.

Material and methods

Data from 35 patients between 2018 and 2021 who received therapy with nivolumab or pembrolizumab for head and neck malignancy were analyzed a

SUBMITTER: Jungbauer F 

PROVIDER: S-EPMC10899674 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature